Search

Displaying results 3071 - 3080 of 7479 in total
  1. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.

  2. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.

  3. Drug

    Acetylcholine

    go.drugbank.com/drugs/DB03128
    ApprovedInvestigational

    It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.

  4. Drug

    Phenylacetic acid

    go.drugbank.com/drugs/DB09269
    Approved

    Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.

  5. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].

    Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLE
  6. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]

  7. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma

  8. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side

  9. Drug

    CAN-106

    go.drugbank.com/drugs/DB18389
    Investigational

    CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.

  10. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collag...